(Q38037649)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920398%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

HLA and pharmacogenetics of drug hypersensitivity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920398%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920398%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Elizabeth J. Phillips

series ordinal

3

object named as

Elizabeth Phillips

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920398%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

2

Simon Mallal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920398%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

1 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920398%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920398%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920398%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920398%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

1285-1306

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920398%20AND%20SRC:MED&resulttype=core&format=json

Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Flucloxacillin-induced liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Genetic association studies in drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Genetic association studies in drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Metabolic and chemical origins of cross-reactive immunological reactions to arylamine benzenesulfonamides: T-cell responses to hydroxylamine and nitroso derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Characterization of drug-specific T cells in lamotrigine hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Activation of T cells by carbamazepine and carbamazepine metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Immune responses to abacavir in antigen-presenting cells from hypersensitive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

T cell recognition of penicillin G: structural features determining antigenic specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Pathogenesis of drug-induced exanthems

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Delayed-type hypersensitivity reaction to paraphenylenediamine is mediated by 2 different pathways of antigen recognition by specific alphabeta human T-cell clones

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Allele-unrestricted presentation of lidocaine by HLA-DR molecules to specific alphabeta+ T cell clones

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Immune self-reactivity triggered by drug-modified HLA-peptide repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Risk factor analysis of hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

B*2707 differs in peptide specificity from B*2705 and B*2704 as much as from HLA-B27 subtypes not associated to spondyloarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Natural HLA class I polymorphism controls the pathway of antigen presentation and susceptibility to viral evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Avidity determines T-cell reactivity in abacavir hypersensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Anticonvulsant hypersensitivity syndrome: incidence, prevention and management

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Medical genetics: a marker for Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Phenytoin-induced Stevens-Johnson syndrome with negative HLA-B*1502 allele in mainland China: two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Oxcarbazepine-induced Stevens-Johnson syndrome: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Sex differences in nevirapine rash

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Liver toxicity caused by nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

The PSORS1 locus gene CCHCR1 affects keratinocyte proliferation in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

The CCHCR1 (HCR) gene is relevant for skin steroidogenesis and downregulated in cultured psoriatic keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Psoriasis-associated genetic polymorphism in North Indian population in the CCHCR1 gene and in a genomic segment flanking the HLA-C region

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

A whole-genome association study of major determinants for host control of HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Rapid HCP5 single-nucleotide polymorphism genotyping: a simple allele-specific PCR method for prediction of hypersensitivity reaction to Abacavir.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Pharmacogenetics of drug hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Pharmacogenetic screening of carbamazepine-induced severe cutaneous allergic reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

A review of drug patch testing and implications for HIV clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA-B locus in Caucasian patients with carbamazepine hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA association of amoxicillin-clavulanate--induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Co-amoxiclav jaundice: clinical and histological features and HLA class II association.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Candidate Gene Analysis Identifies a Polymorphism inHLA-DQB1Associated With Clozapine-Induced Agranulocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Pharmacogenetics of aspirin-intolerant asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Influence of MHC CLASS II in susceptibility to beryllium sensitization and chronic beryllium disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

HLA class II DPB1 and DRB1 polymorphisms associated with genetic susceptibility to beryllium toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Strontium ranelate-induced DRESS syndrome: first two case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Association of HLA-DR11 with the anaphylactoid reaction caused by nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108

Long-Term Safety and Efficacy of Nevirapine-Based Approaches in HIV Type 1-Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.108